A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

This Phase II study (called GOLDEN) is testing whether a drug called golidocitinib — which blocks a protein involved in cancer cell growth — is safe and effective as a first-line treatment for a group of aggressive blood cancers called peripheral T-cell lymphoma (PTCL). **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with specific subtypes of peripheral T-cell lymphoma (including PTCL-NOS, AITL, follicular T-cell lymphoma, or TFH phenotype) - You have not yet received any treatment for this lymphoma - You have at least one measurable tumor - Your overall health is reasonably good (ECOG 0-2) **You may NOT be eligible if...** - You have previously received chemotherapy or JAK/STAT inhibitors for this cancer - You have CNS (brain/spinal) lymphoma - You have active TB, HIV, or active hepatitis B or C - You have significant heart problems including recent heart attack or dangerous heart rhythms - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.